Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen

Translated title of the contribution: Chemotherapy-induced nausea and vomiting in daily clinical practice: A community hospital-based study

Doranne L. Hilarius, Paul H. Kloeg, Elsken Van Der Wall, Joris J G Van Den Heuvel, Chad M. Gundy, Neil K. Aaronson

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. This study investigated: (1) the impact of CINV on patients' health-related quality of life (HRQL) in daily practice; (2) the association between patient characteristics, type of antiemetics and CINV; and (3) the role of CINV in physicians' decisions to modify antiemetic treatment. DESIGN AND METHODS : This prospective, multicenter study was conducted in 9 general hospitals In the Netherlands. During three consecutive chemotherapy cycles, patients used a diary to record episodes of nausea, vomiting and antiemetic use. For each cycle, these ratings were made one day prior to and six days after having received chemotherapy. The influence of CINV on patients' HRQL was evaluated with the Functional Living Index-Emesis (FLIE) questionnaire at day 6 of each treatment cycle. (Changes in) antiemetic use were recorded by the treating nurse. RESULTS: 277 patients were enrolled in the study. Acute and delayed nausea during the first treatment cycle was reported by 39% and 68% of the patients, respectively. The comparable figures for acute and delayed vomiting were 12% and 23%. Approximately one-third of the patients indicated that CINV had a substantial impact on their daily lives. Patients receiving treatment with moderately emetogenic chemotherapy containing anthracycline, reported more acute nausea than patients receiving highly emetogenic chemotherapy. Acute vomiting was associated significantly with change in (i.e., additional) antiemetic treatment. Delayed CINV did not influence antiemetic treatment. CONCLUSION: In daily clinical practice, acute CINV, but not delayed CINV, results in changes in antiemetic treatment. In view of the effects of not only acute but also delayed CINV on daily life, more attention should be paid to adjustment of anti-emetic treatment to cover CINV complaints later during the chemotherapy cycle.

Original languageDutch
Pages (from-to)168-176
Number of pages9
JournalPharmaceutisch Weekblad
Volume147
Issue number42
Publication statusPublished - Oct 19 2012
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hilarius, D. L., Kloeg, P. H., Van Der Wall, E., Van Den Heuvel, J. J. G., Gundy, C. M., & Aaronson, N. K. (2012). Misselijkheid en braken na chemotherapie in de dagelijkse praktijk: Uitkomstenonderzoek in negen algemene ziekenhuizen. Pharmaceutisch Weekblad, 147(42), 168-176.